Durable Efficacy and Manageable Safety Reinforce Taletrectinib's Role in ROS1+ NSCLC

Long-term data on taletrectinib (Ibtrozi) from a World Conference on Lung Cancer (WCLC) poster held few surprises for Jorge Nieva, MD. ROS1 inhibitors have improved tremendously as the field has moved from earlier- to later-generation agents, so long-term disease control was expected. It is still gratifying. "It is delightful, though, every time we see it," Nieva says. An oral therapy that can control disease for many years in most patients is a wonderful option to offer.

Nieva also discussed the ROS1 fusion partner subgroup. Whether the partner was CD74 or another gene, the overall response rate was around 90%, with no major differences between groups. Regardless of a patient's fusion partner, Nieva says, clinicians can be confident that taletrectinib is a highly efficacious choice.

On safety, Nieva describes monitoring as familiar and manageable. Laboratory monitoring for liver function test abnormalities is needed, but it does not differ from routine practice with any tyrosine kinase inhibitor (TKI). The most predictable toxicity is gastrointestinal, which Nieva notes medical oncologists manage all the time. It can be addressed early with dose modifications, antiemetics, antidiarrheal agents, and other supportive care. The goal is to keep patients on an optimal dose while preserving quality of life, so that gastrointestinal adverse events do not limit their ability to live the life they want.

Taken together, Nieva's comments point to a durable oral option with consistent responses across fusion partners and a toxicity profile that standard supportive care can address.

Read the full interview with Dr Nieva.